Manfred B Wischnewsky

Manfred B Wischnewsky

Auto-generated profile, based on publicly available information

Manfred B Wischnewsky

FB Mathematics and Computer Science, University of Bremen, Bremen, Germany

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2020 in European Heart Journal
Verified
Journal Article
Closed access
LNL Christian Napp
L Christian Napp
VCVictoria L Cammann
Victoria L Cammann
MJMilosz Jaguszewski
Milosz Jaguszewski
KSKonrad A Szawan
Konrad A Szawan
MWManfred Wischnewsky
Manfred Wischnewsky
CTChristian Templin
Christian Templin
Aims: Takotsubo syndrome (TTS) is an acute heart failure syndrome, which shares many features with acute coronary syndrome (ACS). Although TTS was initially described with angiographically normal coronary arteries, smaller studies recently indicated a potential coexistence of coronary artery disease (CAD) in TTS patients. This study aimed to determine the coexistence, features, and prognostic role of CAD in a large cohort of patients with TTS. Methods and results: Coronary anatomy and CAD were studied in patients diagnosed with TTS. Inclusion criteria were compliance with the International Takotsubo Diagnostic Criteria for TTS, and availability of original coronary angiographies with ventriculography performed during the acute phase. Exclusion criteria were missing views, poor quality of angiography loops, and angiography without ventriculography. A total of 1016 TTS patients were studied. Of those, 23.0% had obstructive CAD, 41.2% had non-obstructive CAD, and 35.7% had angiographically normal coronary arteries. A total of 47 patients (4.6%) underwent percutaneous coronary intervention, and 3 patients had acute and 8 had chronic coronary artery occlusion concomitant with TTS, respectively. The presence of CAD was associated with increased incidence of shock, ventilation, and death from any cause. After adjusting for confounders, the presence of obstructive CAD was associated with mortality at 30 days. Takotsubo syndrome patients with obstructive CAD were at comparable risk for shock and death and nearly at twice the risk for ventilation compared to an age- and sex-matched ACS cohort. Conclusions: Coronary artery disease frequently coexists in TTS patients, presents with the whole spectrum of coronary pathology including acute coronary occlusion, and is associated with adverse outcome. Trial registration: ClinicalTrials.gov number: NCT01947621.

1 April 2003 in European Journal of Cancer
Verified
Journal Article
Closed access
GMG. Maschmeyer
G. Maschmeyer
FBF.-L. Bertschat
F.-L. Bertschat
KMK.T. Moesta
K.T. Moesta
EHE. Häusler
E. Häusler
THT.K. Held
T.K. Held
PHP. Hohenberger
P. Hohenberger

20 January 2005 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PSPeter Schmid
Peter Schmid
WSWalter Schippinger
Walter Schippinger
TNThorsten Nitsch
Thorsten Nitsch
GHGerdt Huebner
Gerdt Huebner
VHVolker Heilmann
Volker Heilmann
KPKurt Possinger
Kurt Possinger
Purpose: The role of high-dose chemotherapy (HDCT) in metastatic breast cancer remains controversial. Trials with late intensification HDCT have failed to show an advantage in overall survival. This study was initiated to compare up-front tandem HDCT and standard combination therapy in patients with metastatic breast cancer. Patients and Methods: Patients without prior chemotherapy for metastatic disease were randomly assigned to standard combination therapy with doxorubicin and paclitaxel (AT) or double HDCT with cyclophosphamide, mitoxantrone, and etoposide followed by peripheral-blood stem-cell transplantation. HDCT was repeated after 6 weeks. Patients were stratified by menopausal and hormone-receptor status. The primary objective was to compare complete response (CR) rates. Results: A total of 93 patients were enrolled onto the trial. Intent-to-treat CR rates for patients randomized to HDCT and AT were 12.5% and 11.1%, respectively (P = .84). Objective response rates were 66.7% for patients in the high-dose group and 64.4% for patients in the AT arm (P = .82). In an intent-to-treat analysis, there were no significant differences between the two treatments in median time to progression (HDCT, 11.1 months; AT, 10.6 months; P = .67), duration of response (HDCT, 13.9 months; AT, 14.3 months; P = .98), and overall survival (HDCT, 26.9 months; AT, 23.4 months; P = .60). HDCT was associated with significantly more myelosuppression, infection, diarrhea, stomatitis, and nausea and vomiting, whereas patients treated with AT developed more neurotoxicity. Conclusion: This trial failed to show a benefit for up-front tandem HDCT compared with standard combination therapy. HDCT was associated with more acute adverse effects.

1 November 2002 in Oncology
Verified
Journal Article
Closed access
PDF file
PSP. Schmid
P. Schmid
MWM.B. Wischnewsky
M.B. Wischnewsky
OSO. Sezer
O. Sezer
RBR. Böhm
R. Böhm
KPK. Possinger
K. Possinger
Prediction of outcome and individualization of therapeutic strategies are challenging problems in oncology. Predictive parameters for response to hormonal treatment include the expression of hormone receptor, the extent and location of metastatic spread, disease-free interval, patient age, response to prior hormonal therapy, grading, and more recently, some molecular markers like the expression of HER-2/neu. The use of conventional statistics for prediction of response to hormonal treatment is limited by non-linearities and complex interactions between predictive factors. Modern computational mathematical models like artificial neural networks, entropy-based inductive algorithms or χ2 interaction detection algorithms can describe these interactions and generate classification models and decision structures. They can be used to predict the clinical outcome for individual patients. In contrast to conventional methods, the level of confidence for the predictions can reach 90% and more. This might be an important step towards further individualization of therapeutic strategies.

1 March 1999 in European Heart Journal
Verified
Journal Article
Open access
PDF file
TBTh. Budde
Th. Budde
MHM. Haude
M. Haude
HHH.W. Höpp
H.W. Höpp
SKS. Kerber
S. Kerber
GCG. Caspari
G. Caspari
MWM.B. Wischnewsky
M.B. Wischnewsky
AimsThe purpose of this part of the INTERVENT project was (1) to redefine and individually predict post-procedural complications associated with coro

1 September 1999 in European Heart Journal
Verified
Journal Article
Open access
PDF file
WMW. Maier
W. Maier
MEM.F. Enderlin
M.F. Enderlin
TBT. Bonzel
T. Bonzel
NDN. Danchin
N. Danchin
GHG. Heyndrickx
G. Heyndrickx
MWM.B. Wischnewsky
M.B. Wischnewsky
Aims Percutaneous transluminal coronary angioplasty (PTCA) has become the most widely used major intervention in western medicine. However, there is